Short Interest in Aclarion, Inc. (NASDAQ:ACON) Increases By 210.3%

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,230,000 shares, a growth of 210.3% from the November 30th total of 396,400 shares. Currently, 11.8% of the company’s stock are sold short. Based on an average trading volume of 650,100 shares, the days-to-cover ratio is presently 1.9 days.

Aclarion Trading Down 0.2 %

Shares of NASDAQ:ACON traded down $0.00 during trading on Friday, reaching $0.14. The stock had a trading volume of 1,063,424 shares, compared to its average volume of 1,403,075. The stock has a fifty day simple moving average of $0.17 and a two-hundred day simple moving average of $0.22. Aclarion has a 52 week low of $0.10 and a 52 week high of $6.75.

Analyst Ratings Changes

Several research firms recently issued reports on ACON. Ascendiant Capital Markets reduced their price objective on shares of Aclarion from $1.50 to $1.30 and set a “buy” rating for the company in a research note on Wednesday, November 27th. Maxim Group reiterated a “hold” rating on shares of Aclarion in a research note on Friday, December 13th.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.